E-Newsletter - October 2020
Spotlight on Alliance Trials

Alliance Activates SEVEN New Trials, Enrolls Participants in Midst of COVID-19 Pandemic

Alliance A171901: Older non-small lung cancer patients (>/= 70 years of age) treated with first-line MK-3475 (pembrolizumab) +/- chemotherapy (oncologist's/patient's choice)

Early investigator Melisa L. Wong, MD, MAS, of University of California San Francisco, together with Aminah Jatoi, MD, of Mayo Clinic, are leading Alliance A171901, a trial that studies the side effects of pembrolizumab in older patients with or without chemotherapy in treating patients with stage IV non-small cell lung cancer that has recurred and spread to other places in the body.

Alliance A091902: A multicenter phase II trial of paclitaxel with and without nivolumab in taxane naive, and nivolumab and cabozantinib in taxane pretreated subjects with angiosarcoma

Juneko Grilley-Olson, MD, of University of North Carolina at Chapel Hill, is leading Alliance A091902, a trial that studies how well paclitaxel with and without nivolumab works in treating patients with soft tissue sarcoma who have not received taxane drugs (those that block cell growth by stopping cell division), and how well nivolumab and cabozantinib work in treating taxane pretreated patients with angiosarcoma, a specific type of soft tissue sarcoma.

Alliance A021806: A phase III trial of perioperative versus adjuvant chemotherapy for resectable pancreatic cancer

Cristina R. Ferrone, MD, of Massachusetts General Hospital, is leading Alliance A021806, a phase III trial that compares perioperative chemotherapy versus adjuvant chemotherapy for the treatment of pancreatic cancer that can be removed by surgery. Giving chemotherapy before and after surgery may work better in treating patients with pancreatic cancer compared to giving chemotherapy after surgery.

Alliance A081801: Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO

Jacob M. Sands, MD, of the Dana-Farber Cancer Institute, is leading Alliance A080801, a phase III ALCHEMIST trial that compares the addition of pembrolizumab to adjuvant chemotherapy versus chemotherapy alone for the treatment of stage IB (>4cm), II, or IIIA (7th ed) non-small cell lung cancer that has been removed by surgery.

Alliance A221805: Duloxetine to prevent oxaliplatin-induced chemotherapy-induced peripheral neuropathy: A randomized, double-blind, placebo-controlled phase II to phase III study

Ellen M. Lavoie Smith, PhD, RN, FAAN, of the University of Michigan, is leading Alliance A221805, a trial that studies the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer.

Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events

David Kozono, MD, PhD, of the Dana-Farber Cancer Institute/Brigham and Women’s Hospital, is leading Alliance A151804 to establish a national biorepository by collecting research data and samples from patients who experience immunotherapy side effects to store for use in future research studies.

Alliance A031803: Phase II trial o intravesical gemcitabine and MK-3475 (pembrolizumab) in the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer

Michael Woods, MD, of Loyola University Medical Center, is leading Alliance A031803, a phase II trial that studies how well gemcitabine together with pembrolizumab works in treating patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to the bacillus Calmette-Guérin (BCG) vaccine.


For other articles in this issue of Alliance E-News, see below.